AZN AstraZeneca PLC
Trend channel, buy level and 3-month target. Information only, not financial advice.
Above the channel · 12-month channel falling
Closed above resistance (US$158.28). The fitted trend may no longer apply.
- 9-month channel
- US$151.47 – US$157.83 · falling, −28% a year
- 12-month channel read from
- US$151.67 – US$158.28 · falling, −28% a year
- Price in channel
- 529% (0% = floor, 100% = ceiling)
- Ceiling overhead
- none — above both ceilings
- Turns bearish below
- US$151.67
What broke this trend
- The fall
- -25% from US$207.0927 Feb 2026 → 4 Aug 2026
- Whose problem it was
- This company0 of 8 Drug Manufacturers - General peers fell with it
- Does it resolve?
- Temporary falls like it have resolved on the record
- Regained so far
- 38%of what it lost
- What the record says
- 89% of 16 comparable falls came back, typically in 128 days measured on its own peer group
Fell -25% (27 Feb 2026 → 4 Aug 2026); regained 38% so far; company-specific.
Reported at the time: Lung Cancer Research Foundation Launches Small Cell Lung Cancer Grants Worth $750K In Collaboration With AstraZeneca — 24 Feb 2026
Price history, with the path projected 3 months forward
Updated 3:17 PM ET (45 h ago)
- Daily close
- Upper trend line (9 months)
- Lower trend line (9 months)
- The same lines over the last 12 months
- Dashed after today: projected 3 months
- Our buy
- Our target
Our target
No published call: the falling channel’s upper wall (157.87) leaves less than the 6% a call has to clear, and no target is set above a descending wall Levels below are for reference only.
Buy at or below
US$151.45
level as at 1 Nov 2026
Our target
US$157.78
by 2 Nov 2026
Projected move
4.2%
gross, before costs
Price is at or past our target.
- Upper line touches
- 2
- Lower line touches
- 4
- Fit confidence
- 60%
- Fitted
- 1 Nov 2026
Company information
About AstraZeneca PLC
AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with primary and specialty care physicians worldwide, facilitating distribution through a robust network of representatives and local offices across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The firm actively drives innovation through strategic collaborations, partnering with entities such as Neurimmune AG for the development and commercialization of NI006, BenevolentAI for systemic lupus erythematosus drug discovery, Lunit for AI-powered digital pathology risk assessment in NSCLC, and Absci Corporation for AI-driven oncology target identification. Founded in 1992, the company was initially known as Zeneca Group PLC, subsequently rebranding to AstraZeneca PLC in April 1999, and maintains its headquarters in Cambridge, United Kingdom.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Pascal Claude Roland Soriot
- Employees
- 96,100
- Country
- GB
Scorecard
Our own scores from the fundamentals below (not Morningstar ratings).
- Valuation
- —
- Profitability
- —
- Financial health
- —
- Cash generation
- —
Key statistics
- Market cap
- US$255.21B
- Enterprise value
- —
- Beta
- 0.21
- Avg volume
- 2.94M
- Revenue per share
- —
- Dividend yield
- —
- 52-week range
- 145.8-212.71
- Exchange
- NYSE
Key ratios
- P/E (TTM)
- —
- PEG
- —
- Price / sales
- —
- Price / book
- —
- EV / EBITDA
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Current ratio
- —
- Quick ratio
- —
- Debt / equity
- —
- Interest cover
- —
Income statement
Balance sheet
Cash flow
Trend lines are fitted to past swing highs and lows and may not continue. Information only, not financial advice.